Literature DB >> 27888453

Evaluation of nucleoside reverse transcriptase inhibitor dosing during continuous veno-venous hemofiltration.

Milena M McLaughlin1,2, Inela Masic3, Lana Gerzenshtein4.   

Abstract

Background Unpredictable drug concentrations may lead to suboptimal exposure to nucleoside reverse transcriptase inhibitors (NRTIs) due to inadequate doses administered during continuous veno-venous hemofiltration (CVVH), which in turn may lead to decreased antiretroviral efficacy and possibly further HIV disease progression. Objective To compare administered doses of NRTIs to calculated doses of NRTIs to evaluate if patients were expected to have a favorable pharmacokinetic exposure profile while receiving CVVH. Methods The NRTI dose was compared to a table of recommendations based on a mathematical formula that estimates the amount of drug expected to be removed during CVVH. Results Twelve patients were on 27 NRTIs. Eleven (41%) NRTI doses were expected to provide a favorable pharmacokinetic profile based on pharmacokinetic mathematical calculations. Conclusion The majority of NRTIs were potentially not optimally dosed based on proposed pharmacokinetic calculations.

Entities:  

Keywords:  Continuous veno-vous hemofiltration; HIV; NRTIs; Nucleoside reverse transcriptase inhibitor; Pharmacokinetics

Mesh:

Substances:

Year:  2016        PMID: 27888453     DOI: 10.1007/s11096-016-0401-7

Source DB:  PubMed          Journal:  Int J Clin Pharm


  10 in total

1.  Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Samir K Gupta; Joseph A Eustace; Jonathan A Winston; Ivy I Boydstun; Tejinder S Ahuja; Rudolph A Rodriguez; Karen T Tashima; Michelle Roland; Nora Franceschini; Frank J Palella; Jeffrey L Lennox; Paul E Klotman; Sharon A Nachman; Stephen D Hall; Lynda A Szczech
Journal:  Clin Infect Dis       Date:  2005-04-22       Impact factor: 9.079

Review 2.  Drug dosing adjustments during continuous renal replacement therapies.

Authors:  T A Golper; M A Marx
Journal:  Kidney Int Suppl       Date:  1998-05       Impact factor: 10.545

Review 3.  Continuous hemofiltration in the treatment of acute renal failure.

Authors:  L G Forni; P J Hilton
Journal:  N Engl J Med       Date:  1997-05-01       Impact factor: 91.245

4.  Dosing nucleoside reverse transcriptase inhibitors in adults receiving continuous veno-venous hemofiltration.

Authors:  Milena M McLaughlin; Abeer T Ammar; Lana Gerzenshtein; Kimberly K Scarsi
Journal:  Clin Drug Investig       Date:  2015-04       Impact factor: 2.859

5.  Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.

Authors:  Courtney V Fletcher; Peter L Anderson; Thomas N Kakuda; Timothy W Schacker; Keith Henry; Cynthia R Gross; Richard C Brundage
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

Review 6.  Renal toxicity associated with antiretroviral therapy.

Authors:  Leonardo Calza
Journal:  HIV Clin Trials       Date:  2012 Jul-Aug

7.  Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.

Authors:  Massimiliano Fabbiani; Simona Di Giambenedetto; Laura Bracciale; Alessandra Bacarelli; Enzo Ragazzoni; Roberto Cauda; Pierluigi Navarra; Andrea De Luca
Journal:  J Antimicrob Chemother       Date:  2009-04-27       Impact factor: 5.790

8.  Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.

Authors:  Shigehiko Uchino; Rinaldo Bellomo; Hiroshi Morimatsu; Stanislao Morgera; Miet Schetz; Ian Tan; Catherine Bouman; Ettiene Macedo; Noel Gibney; Ashita Tolwani; Heleen Oudemans-van Straaten; Claudio Ronco; John A Kellum
Journal:  Intensive Care Med       Date:  2007-06-27       Impact factor: 17.440

Review 9.  Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.

Authors:  Sarah M McCabe; Qing Ma; Judianne C Slish; Linda M Catanzaro; Neha Sheth; Robert DiCenzo; Gene D Morse
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  Acute kidney injury in patients with human immunodeficiency virus infection.

Authors:  J Prakash; T Gupta; S Prakash; S S Rathore; S Sunder
Journal:  Indian J Nephrol       Date:  2015 Mar-Apr
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.